With second-generation tracers such as [18F]PI-2620 this has been greatly reduced (Leuzy et al., 2019), allowing for a more reliable read-out of binding patterns, which becomes even more relevant considering that most but not all (Pegueroles et al., 2023; Nuebling et al., 2021) studies in DS so far have leveraged first-generation tau tracers, resulting in the need of the exclusion of the striatum due to apparent off-target binding (Hartley et al., 2022; Rafii et al., 2017; Grigorova et al., 2022; Zammit et al., 2021; Tudorascu et al., 2020; Handen et al., 2021). The gene discussed is MAPT; the disease is Dravet syndrome.